TY - JOUR
T1 - The pain of antisense
T2 - In vivo application of antisense oligonucleotides for functional genomics in pain and analgesia
AU - Stone, Laura S.
AU - Vulchanova, Lucy
PY - 2003/8/15
Y1 - 2003/8/15
N2 - As the genomic revolution continues to evolve, there is an increasing demand for efficient and reliable tools for functional characterization of individual gene products. Antisense oligonucleotide-mediated knockdown has been used successfully as a functional genomics tool in animal models of pain and analgesia yet skepticism regarding the validity and utility of antisense technology remains. Contributing to this uncertainty are the lack of systematic studies exploring antisense oligonucleotide use in vivo and the many technical and methodological challenges intrinsic to the method. This article reviews the contributions of antisense oligonucleotide-based studies to the field of pain and analgesia and the general principles of antisense technology. A special emphasis is placed on technical issues surrounding the successful application of antisense oligonucleotides in vivo, including sequence selection, antisense oligonucleotide chemistry, DNA controls, route of administration, uptake, dose-dependence, time-course and adequate evaluation of knockdown.
AB - As the genomic revolution continues to evolve, there is an increasing demand for efficient and reliable tools for functional characterization of individual gene products. Antisense oligonucleotide-mediated knockdown has been used successfully as a functional genomics tool in animal models of pain and analgesia yet skepticism regarding the validity and utility of antisense technology remains. Contributing to this uncertainty are the lack of systematic studies exploring antisense oligonucleotide use in vivo and the many technical and methodological challenges intrinsic to the method. This article reviews the contributions of antisense oligonucleotide-based studies to the field of pain and analgesia and the general principles of antisense technology. A special emphasis is placed on technical issues surrounding the successful application of antisense oligonucleotides in vivo, including sequence selection, antisense oligonucleotide chemistry, DNA controls, route of administration, uptake, dose-dependence, time-course and adequate evaluation of knockdown.
KW - Animal model
KW - Central nervous system
KW - Gene targeting
KW - Intrathecal
KW - Knockdown
KW - Mouse
KW - Nociception
KW - Rat
UR - http://www.scopus.com/inward/record.url?scp=0142075731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142075731&partnerID=8YFLogxK
U2 - 10.1016/S0169-409X(03)00105-4
DO - 10.1016/S0169-409X(03)00105-4
M3 - Article
C2 - 12935946
AN - SCOPUS:0142075731
SN - 0169-409X
VL - 55
SP - 1081
EP - 1112
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
IS - 8
ER -